Fraunhofer ITEM – pioneers for sustainable health

Fraunhofer ITEM aims to protect man from health hazards in our industrialized world and to contribute to the development of novel therapeutic approaches. Focusing on lung and inhalation, Fraunhofer ITEM has pooled its expertise in three business areas:

In the business area Drug Development, we develop and test novel medications against respiratory diseases – in particular asthma, hay fever, COPD, idiopathic pulmonary fibrosis (IPF) and infections. Scientific expertise covers manufacturing of biologics, preclinical and clinical development.

In the business area Chemical Safety and Assessment we determine the risks from potentially harmful substances and support the development of new products to protect human health and the environment. Scientific expertise includes toxicology testing, exposure assessment, analytical methods, regulatory research and risk assessment.

The business area Translational Biomedical Engineering offers many years of experience in the development of medical devices – specifically medical aerosolizers and neuro-implants – including testing and testing scenarios, safety and risk assessment.

All business areas offer regulatory support. Numerous test systems are available, including in-vitro, ex-vivo, in-vivo and in-silico models Studies can be performed in compliance with GXP regulations.

A Regensburg-based division is dedicated to personalized tumor therapy including development of diagnostic tests to enable early detection of disseminated cancer cells and prediction of the response to therapy of metastatic progenitor cells.

Fraunhofer ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization.